Find investors
← Back to all investors
HT
ResearchedAngel Investors

Hiroshi Takaoka

Corporate Officer

Angel InvestorsSeed Round
Pitch Hiroshi

Get their honest, personalized take on your startup.

Sign in to pitch Hiroshi

At a glance

Full Name
Hiroshi Takaoka
Title
Corporate Officer
Firm
Keio Innovation Initiative, Inc. (KII)
Firm Type
Venture Capital
Investment Stage
Angel, Seed, Pre-Series A, Series A, Series B and later, Pre-IPO
Check Size
Up to ¥500 million
Target Company Profile
Deep-tech and research-driven startups, including university-originated ventures; KII says it supports projects from the seed period through market entry and beyond.
Sector Focus
Digital technology, AI, big data, IoT, robotics, medical and healthcare, biotechnology, pharmaceuticals, medical devices, cloud computing, telecommunications, wearables, sports technology
Geographic Focus
Japan; overseas investments considered case by case
Location
Tokyo, Japan

Background

Hiroshi Takaoka is a Japanese venture investor associated with Keio Innovation Initiative, Inc. (KII), the venture capital firm established in 2015 to commercialize academic research and inventions, especially those connected to Keio University and broader Japanese research ecosystems.

Takaoka graduated from Keio University’s Faculty of Economics. Before joining KII, he built a career of more than 24 years at Nomura Securities. Public Japanese startup databases and investor profiles describe him as having served as branch manager in locations including Kashiwa, Mito, Nagoya Station, and Tokushima, where he was involved in supporting local venture companies. He also held head-office roles including General Manager of Human Resources Planning and General Manager of Examination / Dispute Assessment functions.

In April 2018, Takaoka was reported as joining KII as a Corporate Officer. KII’s current public team page no longer lists him among active team members, so his current day-to-day role should be verified directly before outreach. His KII-era profile emphasizes using the knowledge and network developed during his Nomura Securities career to support startups.

Investment Thesis & Focus

  • KII’s stated purpose is to “Turn academic research and invention into a world-changing business,” with an emphasis on helping technologies born in university research labs gain the business growth support needed for social implementation.
  • KII focuses on deep-tech companies, especially digital technology and life sciences / healthcare.
  • KII is positioned as a university VC that can lead difficult-to-evaluate seed and early-stage technology investments.
  • Reported investment stages span Angel, Seed, Pre-Series A, Series A, Series B and later, and Pre-IPO.
  • Reported maximum investment amount is up to ¥500 million, with KII described as actively making lead investments.
  • KII’s review process reportedly considers the team, opportunity, market/regulatory/technology context, and deal terms; the process can take as little as about two months from first discussion to investment execution.
  • KII’s founder-facing posture is relatively open: StartupList reports that KII welcomes consultations from researchers, first-time founders, student founders, young founders, and working professionals.

Notable Investments

  • Luxonus - Develops and sells imaging devices using photoacoustic / light-ultrasound technology.
  • CureApp - Develops evidence-based therapeutic software medical devices, including prescription digital therapeutics.
  • Kringle Pharma - Osaka University-originated biotechnology company developing HGF-based regenerative medicines and biopharmaceuticals.
  • Synspective - Develops, operates, and commercializes SAR satellite data and satellite-data applications.
  • APB Japan - Develops and manufactures next-generation all-polymer lithium-ion batteries.
  • Modulus Discovery - Drug-discovery company using computational chemistry.
  • BONX - Develops wearable communication devices.
  • Institution for a Global Society - Uses AI for human-capital matching and English e-learning.
  • Cellusion - Regenerative-medicine company developing iPSC-derived corneal endothelial cell therapies.
  • AdipoSeeds - Commercializes regenerative-medicine products based on adipose-derived cells.
  • xenodata lab - Develops AI-driven financial information analysis tools using natural-language processing.
  • SENSY - Artificial-intelligence company with AI development and internet media businesses.
  • Motion Lib - Works on real-haptics technology.
  • IDAC Theranostics - Pharmaceutical development company.

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.